Garcia Maria L, Kaczorowski Gregory J
Department of Ion Channels, Merck Research Laboratories, Post Office Box 2000, Rahway, NJ 07065, USA.
Sci STKE. 2005 Sep 20;2005(302):pe46. doi: 10.1126/stke.stke.3022005pe46.
The potassium channel superfamily presents a rich source of targets for therapeutic intervention. Indeed, the development of specific potassium channel modulators could lead to the effective treatment of various diseases for which current therapies are clearly suboptimal. Numerous factors play a role in determining whether the successful clinical development of such drugs can ever be achieved. However, the large body of information accumulated over the last few years on the structure and function of potassium channels is expected to drive drug-development efforts in the pharmaceutical industry on these targets, with the ultimate goal of developing therapies that will improve patient quality of life.
钾通道超家族为治疗干预提供了丰富的靶点来源。事实上,开发特异性钾通道调节剂可能会有效治疗目前疗法明显欠佳的多种疾病。众多因素在决定此类药物能否成功实现临床开发方面发挥着作用。然而,过去几年积累的关于钾通道结构和功能的大量信息有望推动制药行业针对这些靶点开展药物研发工作,最终目标是开发出能改善患者生活质量的疗法。